key: cord-0697710-a1wpgqof
authors: Battesti, Gilles; El Khalifa, Jihane; Abdelhedi, Nour; Ferre, Valentine; Bouscarat, Fabrice; Picard-Dahan, Catherine; Brunet-Possenti, Florence; Collin, Gilles; Lavaud, Justine; Le Bozec, Patrick; Rousselot, Marion; Tournier, Amélie; Lheure, Coralie; Couvelard, Anne; Hacein-Bey-Abina, Salima; Abina, Amine.M.; Charpentier, Charlotte; Mignot, Sabine; Nicaise, Pascale; Descamps, Diane; Deschamps, Lydia; Descamps, Vincent
title: New insights in COVID-19-associated chilblains: a comparative study with chilblain lupus erythematosus
date: 2020-07-03
journal: J Am Acad Dermatol
DOI: 10.1016/j.jaad.2020.06.1018
sha: b72a711dcc4c867c3fe2b379d5bd28478c4c5cde
doc_id: 697710
cord_uid: a1wpgqof

nan

The clinico-biological findings of EC and CLE cases are summarized in Table 1 

Our 7 EC cases were histologically similar to CLE. High expression of CD123 and MxA were observed 202 in both groups

These results confirmed that chilblains may be considered as a manifestation of high production of 205

These patients may exhibit only IFN-I associated symptoms 206 or minor forms of COVID-19 infection. High level of IFN-I was associated with moderate cases

COVID-19 2 . Interferon-induced proteins such as IFITM (interferon-induced trans-membrane) 1, 2 and 208 3 also inhibits early replication of several enveloped RNA viruses

In addition, active viral replication may not be necessary to mount an efficient IFN response in SARS

IFN-I may also suppress antibody that explain the negativity of the serologies in most 211 patients with EC

-2 infection may induce in some predisposed patients a high production of IFN-I responsible 213 for a high innate immune protective response

This hypothesis provides additional arguments to propose early IFN treatment for infected high-risk

Chilblains are a common cutaneous 229 finding during the COVID-19 pandemic: a retrospective nationwide study from France. 230

Impaired type I interferon activity and exacerbated inflammatory responses in severe 232 Covid-19 patients | medRxiv

IFITM Proteins Inhibit Entry Driven by the 235 MERS-Coronavirus Spike Protein: Evidence for Cholesterol-Independent Mechanisms

Unraveling the 238 complexities of the interferon response during SARS-CoV infection

Interferon-driven deletion of antiviral B cells at the 241 onset of chronic infection

Classification of the cutaneous 243 manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain 244 with 375 cases

COVID-19) infection-induced 246 chilblains: A case report with histopathologic findings. JAAD Case Rep

Histologic features of long lasting 249 chilblain-like lesions in a pediatric COVID-19 patient

A case of COVID-19 presenting in clinical picture resembling 252 chilblains disease. First report from the Middle East

Assessment of Clinical Response to

Kinase Inhibition in Patients With Familial Chilblain Lupus and TREX1 Mutation

Identification of Residues Controlling Restriction 258 versus Enhancing Activities of IFITM Proteins on Entry of Human Coronaviruses